Humira Biosimilars – Update for October Formularies
Our recent August Pharmacy and Therapeutics (P&T) Committee meeting reviewed the release of various Humira® biosimilars. Staying true to our commitment to drive greater affordability for both clients and members, we finalized decisions that will affect our formularies on October 1, 2023. Focused on lowest net cost, our decisions strive to provide the most benefit to both clients and members.
HUMIRA and biosimilars
Beginning in February 2023 and culminating in July 2023, ten biosimilar products to Humira have been released. These products are designed to have the same clinical effect as those of a reference drug that has previously been licensed. Current biosimilars now available to Humira are as follows:
Adalimumab-adaz (Sandoz)
Adalimumab-fkjp (Mylan)
Amjevita™ (Amgen)
Cyltezo® (Boehringer Ingelheim)
Hadlima™(Organon)
Hulio® (Mylan)
Hyrimoz® (Sandoz)
Idacio® (Fresenius Kabi)
Yuflyma® (Celltrion)
Yusimry® (Coherus)
Formulary Updates
Due to these releases, additional rebates are now being offered from Abbvie, the manufacturer of Humira. In addition, significant cost savings compared to Humira are now available for the biosimilars listed above. With the complexity of upfront product costs, availability of rebates, manufacturer rebate bundling, and patient copay assistance, the Navitus formularies will be updated on October 1, 2023 with the following:
Added:
Adalimumab-adaz
Adalimumab-fkjp
Hadlima™
Remaining: Humira
Removed: Amjevita™
Our teams will continue to monitor the evolving landscape of biosimiliar products and drug pipeline activity to keep you informed.
WRITTEN BY BRENT EBERLE
As Senior Vice President, Chief Pharmacy Officer, Brent oversees Navitus’ health strategies division, which is responsible for clinical and population health initiatives, drug utilization review programs, formulary and rebate management, and specialty pharmacy operations.
Stay Informed and Connected
Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.
Examining Trends that Drive Informed Decisions
Now Available: 8th Annual Drug Trend Report
See the latest results and access industry insights you need to navigate current trend drivers.
Related blogs
Navigating Healthcare and Improving Outcomes
Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars
Authors: Justin Arzt, PharmD; Agata Siwak, PharmD, MSBA; Marnie Wickizer, PharmD, AE-C, CDCES; Ryan Schmidt, PharmD; Robert Topp, RN, PhD; Matt Hustad, PharmD All authors are employees of Navitus Health Solutions. Abstract Adalimumab biosimilar adoption…
PBM 101: Why the Model Matters
In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are conduits of expertise, analytics and savings opportunities, poised to deliver exceptional health care while driving down costs. They coordinate between drug manufacturers,…
Associate Resource Group Spotlight: Green Team
The Green Team believes that small changes lead to significant impact. Whether its reducing waste, conserving energy or implementing eco-friendly initiatives, they serve as an internal hub for expertise regarding environmental sustainability….
PBM 101: The Three PBM Business Models
In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are regarded by the media as intermediaries between drug manufacturers, pharmacies, health plans and plan sponsors. But they’re so much more than that. PBMs act as conduits…
An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)
This study examines the impact of implementing an automated point-of-sale diagnosis verification system for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared to traditional utilization management approaches….
Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings
As the nation’s first 100% transparent, pass-through PBM, we continue to advance medication affordability by prioritizing upfront, real-time savings over rebated models….
Achieving Outstanding Results with Tailored Network Strategies
A medium-sized city in Michigan with 1,350 members was seeking ways to lower its pharmacy benefit costs, which were growing under its existing traditional pharmacy benefit manager (PBM). With its member covered by a two-tier, open formulary including…
Breaking Through Barriers with Value-Based Plan Design
Facing increased pharmacy benefit expenses, Blain’s Farm and Fleet, a Midwestern employer group, desired to improve plan performance. Specifically it was interested in educating eligible members about the benefits available to them, promoting cost-effective…
Finding a Solution to Lower Prescription Drug Costs
The Rural Arizona Group Health Trust (RAGHT) wanted to gain better control of its escalating drug trend with its large, traditional pharmacy benefit manager (PBM). Having only worked with traditional PBMs in the past, RAGHT was interested in exploring…
